Tagworks Pharmaceuticals B.V.

https://www.tagworkspharma.com

LinkedIn: https://www.linkedin.com/company/tagworks-pharmaceuticals

Tagworks Pharmaceuticals, pioneer of the Click-to-Release approach, is a precision therapy company, leveraging its technology platform, which is protected by a broad patent estate, to develop a new standard of care for patients suffering from severe diseases including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a clinically-validated, pan-carcinoma target that so far has remained out of reach of current ADC therapies. Tagworks’ technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. *

	Start	2011-01-01 established (s-off)
	Predecessor	Philips Healthcare (sector of Philips business group)
	Industry	Click-to-Release technology
	Industry 2	TGW101 (ADC targeting TAG72, Tagworks Pharmaceuticals)
	Person	Robillard, Marc (Tagworks Pharmaceuticals 202306 CEO + Co-Founder before Philips Healthcare)
	Person 2	Martin, Chris (Auven Therapeutics 201506 CEO of ADC Therapeutics before CEO of Spirogen Ltd)

	Region	Nijmegen
	Country	Netherlands
	Street	1 Toernooiveld
	City	6525 ED Nijmegen
	Tel	+31-85-800-8550
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Tagworks Pharmaceuticals B.V.. (6/22/23). "Press Release: Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics". Nijmegen & Boston, MA.

		Record changed: 2024-02-12